News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026

Akari Therapeutics to Present at the 2026 Biotech Showcase

Akari Therapeutics (NASDAQ:AKTX) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating and a $1.00 price target on the stock.

Akari Therapeutics Issues 2025 End of Year Letter to Shareholders

Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial

Top News Decliners

5/1 Akari Therapeutics Announces Positive Topline Results from Fully Recruited Phase II Study of Nomacopan in Bullous Pemphigoid Patients -24.4%

3/13 Akari Therapeutics PLC (NASDAQ: AKTX) had its price target lowered by analysts at B. Riley from $7.00 to $5.00. They now have a "buy" rating on the stock. -15.4%

4/2 Akari Therapeutics PLC (NASDAQ: AKTX) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $5.00 price target on the stock. -15.2%

9/13 Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid -12.8%

10/10 Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th EADV Congress -12.0%

8/30 Thinking about buying stock in Aurora Cannabis, Akari Therapeutics, Big Lots, Campbell Soup, or Walt Disney Co? -11.1%

3/11 Form D Akari Therapeutics Plc -10.5%

8/9 Akari Therapeutics announces new data demonstrating synergistic benefits of nomacopan’s bifunctional C5 and LTB4 inhibitory activity in pemphigoid disease -9.8%

12/23 Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) Following the Opening of its IND -8.9%

9/3 Akari Therapeutics to Participate in Citi and H.C. Wainwright Conferences in Early September -8.2%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}